About
Technology
Issues
FAQ
Links
Official Page
Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.